Investors

List of the current and past investors into Oxford Immunotec Ltd with their respective financial instruments.

Profile Country Phone Round
Albion Ventures LLP Albion Ventures was established to generate long term investment returns through making venture capital investments in smaller companies United Kingdom +44 (20) 7601-1850 N/A
Clarus Ventures LLC Life sciences venture capital firm United States +1 (617) 949-2200 Series D
Clarus Ventures LLC Life sciences venture capital firm United States +1 (617) 949-2200 Venture
Clarus Ventures LLC Life sciences venture capital firm United States +1 (617) 949-2200 Series C
DFJ Esprit LLP Venture capital firm. United Kingdom +44 (1223) 307-770 Venture
DFJ Esprit LLP Venture capital firm. United Kingdom +44 (1223) 307-770 Series D
Dow Chemical Co United States Series B
Dow Chemical Co United States Venture
Dow Chemical Co United States Series D
Dow Chemical Co United States Series C
Imperial Innovations Ltd United Kingdom +44 (20) 7581-4949 Venture
Invesco Perpetual Life Ltd United Kingdom Venture
Kaiser Permanente Ventures (KP Ventures) The corporate venture capital arm of Kaiser Permanente United States +1 (510) 267-7300 Series D
Kaiser Permanente Ventures (KP Ventures) The corporate venture capital arm of Kaiser Permanente United States +1 (510) 267-7300 Venture
New Leaf Venture Partners (NLV) United States +1 (646) 871-6400 Series D
New Leaf Venture Partners (NLV) United States +1 (646) 871-6400 Venture
NTEC Kuwait Series C
Prelude Trust PLC United Kingdom Series C
Prelude Ventures Ltd United Kingdom Series B
Quester Capital Management Ltd United Kingdom Series A
Quester Ltd United Kingdom Series C
Quester Ltd United Kingdom Series B
SPARK Ventures PLC A leading, publicly quoted venture capital investor in Europe United Kingdom +44 (20) 7851-7777 Venture
SPARK Ventures PLC A leading, publicly quoted venture capital investor in Europe United Kingdom +44 (20) 7851-7777 Series D
Wellington Partners [US] United States Venture
Wellington Partners [US] United States Series D
Wellington Partners [US] United States Series C